Urinary biomarkers for immunotherapy response in urothelial carcinoma: current status and future outlook.

IF 3.6 3区医学 Q1 PATHOLOGY

Expert Review of Molecular Diagnostics Pub Date : 2025-10-24 DOI:10.1080/14737159.2025.2573459

Shota Inoue, Marcin Miszczyk, Agata Suleja, Akihiro Matsukawa, Keiichiro Miyajima, Alessandro Dematteis, Angelo Cormio, Navid Roessler, Ahmed R Alfarhan, Ichiro Tsuboi, Tatsushi Kawada, Satoshi Katayama, Takehiro Iwata, Kensuke Bekku, Pierre I Karakiewicz, Leonardo Oliveira Reis, Motoo Araki, Shahrokh F Shariat

{"title":"Urinary biomarkers for immunotherapy response in urothelial carcinoma: current status and future outlook.","authors":"Shota Inoue, Marcin Miszczyk, Agata Suleja, Akihiro Matsukawa, Keiichiro Miyajima, Alessandro Dematteis, Angelo Cormio, Navid Roessler, Ahmed R Alfarhan, Ichiro Tsuboi, Tatsushi Kawada, Satoshi Katayama, Takehiro Iwata, Kensuke Bekku, Pierre I Karakiewicz, Leonardo Oliveira Reis, Motoo Araki, Shahrokh F Shariat","doi":"10.1080/14737159.2025.2573459","DOIUrl":null,"url":null,"abstract":"Introduction: Immunotherapy treatments, such as intravesical Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer (NMIBC) and systemic immune checkpoint inhibitors (ICIs) for all stages are central to the management of urothelial carcinoma (UC). Biomarkers that are prognostic or predictive and that help in monitoring these therapies are needed to guide and improve efficacy and tolerability. In this review, we evaluated the current landscape of urinary biomarkers for predicting response to immunotherapy (BCG and ICIs) in UC patients and their potential to guide personalized treatment strategies.Areas covered: This narrative review summarizes current evidence on urinary biomarkers for predicting responses to BCG and ICIs therapies in UC, based on a comprehensive search of PubMed literature.Expert opinion: Urinary biomarkers show significant potential for transforming UC immunotherapy by facilitating personalized treatment. Despite promising initial data for various analytes, large-scale validation and standardization must be addressed. We still need better, faster, easier, cheaper, reliable and valid urine-based biomarkers. Future research should focus on multiplex panels to enhance patient stratification and improve therapeutic outcomes and follow-up.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"1-7"},"PeriodicalIF":3.6000,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Molecular Diagnostics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737159.2025.2573459","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Immunotherapy treatments, such as intravesical Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer (NMIBC) and systemic immune checkpoint inhibitors (ICIs) for all stages are central to the management of urothelial carcinoma (UC). Biomarkers that are prognostic or predictive and that help in monitoring these therapies are needed to guide and improve efficacy and tolerability. In this review, we evaluated the current landscape of urinary biomarkers for predicting response to immunotherapy (BCG and ICIs) in UC patients and their potential to guide personalized treatment strategies.

Areas covered: This narrative review summarizes current evidence on urinary biomarkers for predicting responses to BCG and ICIs therapies in UC, based on a comprehensive search of PubMed literature.

Expert opinion: Urinary biomarkers show significant potential for transforming UC immunotherapy by facilitating personalized treatment. Despite promising initial data for various analytes, large-scale validation and standardization must be addressed. We still need better, faster, easier, cheaper, reliable and valid urine-based biomarkers. Future research should focus on multiplex panels to enhance patient stratification and improve therapeutic outcomes and follow-up.

查看原文本刊更多论文

尿路上皮癌免疫治疗反应的尿液生物标志物：现状和未来展望。

免疫疗法治疗，如膀胱内卡介苗（BCG）治疗非肌肉浸润性膀胱癌（NMIBC）和所有阶段的系统性免疫检查点抑制剂（ICIs）是尿路上皮癌（UC）治疗的核心。需要具有预后或预测性并有助于监测这些治疗的生物标志物来指导和提高疗效和耐受性。在这篇综述中，我们评估了尿生物标志物预测UC患者对免疫治疗（BCG和ICIs）反应的现状及其指导个性化治疗策略的潜力。涵盖领域：本文基于PubMed文献的全面检索，总结了尿生物标志物预测UC患者对BCG和ICIs治疗反应的现有证据。专家意见：尿液生物标志物通过促进个性化治疗显示出改变UC免疫治疗的巨大潜力。尽管各种分析物的初始数据很有希望，但必须解决大规模验证和标准化问题。我们仍然需要更好、更快、更容易、更便宜、可靠和有效的基于尿液的生物标志物。未来的研究应侧重于多重小组，以加强患者分层，改善治疗效果和随访。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Molecular Diagnostics 医学-病理学

CiteScore

6.60

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： Expert Review of Molecular Diagnostics (ISSN 1473-7159) publishes expert reviews of the latest advancements in the field of molecular diagnostics including the detection and monitoring of the molecular causes of disease that are being translated into groundbreaking diagnostic and prognostic technologies to be used in the clinical diagnostic setting. Each issue of Expert Review of Molecular Diagnostics contains leading reviews on current and emerging topics relating to molecular diagnostics, subject to a rigorous peer review process; editorials discussing contentious issues in the field; diagnostic profiles featuring independent, expert evaluations of diagnostic tests; meeting reports of recent molecular diagnostics conferences and key paper evaluations featuring assessments of significant, recently published articles from specialists in molecular diagnostic therapy. Expert Review of Molecular Diagnostics provides the forum for reporting the critical advances being made in this ever-expanding field, as well as the major challenges ahead in their clinical implementation. The journal delivers this information in concise, at-a-glance article formats: invaluable to a time-constrained community.